James L. Winkle College of Pharmacy, University of Cincinnati Academic Health Center, 3225 Eden Avenue, Cincinnati, OH 45267-0004, USA.
Oncol Rep. 2011 Feb;25(2):433-41. doi: 10.3892/or.2010.1106. Epub 2010 Dec 13.
Although extensive literature exists on cancer biomarkers few have found entry into clinical use. In particular, the cancer metastasis gene Osteopontin has been investigated extensively but it has not yet been applied to routine diagnostics. Here, we conduct a meta-analysis of data from the published literature and from RNA microarrays deposited in Oncomine. Osteopontin has been associated with 34 cancers. It is a marker for breast, cervical, colorectal, head and neck, liver, lung, ovarian and prostate cancers, as well as for sarcoma. Osteopontin is overexpressed in the metastases of colorectal cancers, lung cancers and melanomas, but not in ovarian cancer. Further, Osteopontin is indicative of the underlying mechanism of transformation only in certain virally induced tumors, where its function as a TH1 cytokine likely plays important roles. These results refine the value of Osteopontin as a cancer biomarker.
尽管有大量关于癌症生物标志物的文献，但很少有标志物能进入临床应用。特别是癌症转移基因 Osteopontin 已经被广泛研究，但尚未应用于常规诊断。在这里，我们对已发表文献中的数据以及 Oncomine 中已发表的 RNA 微阵列数据进行了荟萃分析。Osteopontin 与 34 种癌症有关。它是乳腺癌、宫颈癌、结直肠癌、头颈部癌、肝癌、肺癌、卵巢癌和前列腺癌以及肉瘤的标志物。Osteopontin 在结直肠癌、肺癌和黑色素瘤的转移中过度表达，但在卵巢癌中没有。此外，Osteopontin 仅在某些病毒诱导的肿瘤中表明转化的潜在机制，在这些肿瘤中，其作为 TH1 细胞因子的功能可能发挥重要作用。这些结果细化了 Osteopontin 作为癌症生物标志物的价值。
